Vertex Pharmaceuticals missed Wall Street estimates for quarterly results on Monday due to lower-than-expected sales of its ...

Morgan Stanley analyst Matthew Harrison maintained an Equal-Weight rating and raised the price target from $450 to $459 on ...

Vertex Pharmaceuticals reports first-quarter financial results after the market close on Monday. Here's a look at the key highlights from the period.

Vertex said its profit fell due to higher operating expenses and a $379 million intangible asset impairment charge associated with treatment for Type 1 diabetes patients, which the company said in ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) in Q1 CY2025 as sales rose 3% year on year to $2.77 billion. The company ...

Discover Vertex Pharmaceuticals' Q1 2025 earnings insights, with 3% revenue growth, key product launches like JOURNAVX & ALYFTREK, & raised ...

Vertex Pharmaceuticals (NASDAQ:VRTX) missed on the top and bottom lines in its Q1 financial results and also raised the low ...

Jenburkt Pharmaceuticals Ltd., incorporated in the year 1985, is a company (having a market cap of Rs 456.95 Crore) operating in Pharmaceuticals sector. Jenburkt Pharmaceuticals Ltd. key ...

Sun Pharmaceutical Industries Ltd., incorporated in the year 1993, is a company (having a market cap of Rs 4,38,934.34 Crore) operating in Pharmaceuticals sector. Sun Pharmaceutical Industries Ltd.